SAMHY2NCT05427461
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
StatusActive, Not Recruiting
PhaseNot applicable
SponsorInstitut Claudius Regaud
Primary completion (estimated)
At risk: Primary completion moved at least 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 9 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Jul 2026 to May 2027
- Eligibility criteria expanded, about 12 words
- Primary endpoints: details revised at 1 of 1 entry
- Secondary endpoints: details revised at 1 of 1 entry
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Minor Start date changed from estimate of Jan 2023 to Jan 13, 2023v7
- Minor Start date: Dec 2022 to Jan 2023v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
Show 3 earlier versionsHide 3 earlier versions
- Minor Site contact updatedv4
- Notable Start date: Oct 2022 to Dec 2022v3
- Notable Start date: Jul 2022 to Oct 2022v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The longitudinal evolution of rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood.
Timeframe: 24 months after the end of inclusions.
Secondary (1)
Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.
Arms and interventions
Patient with leiomyosarcomaOther
Other: Blood samples will be collected at different times.
Sites
1 site in 1 country
- Institut Universitaire du Cancer Toulouse - OncopoleToulouse, France